NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Compass Diversified (“Compass” or the “Company”) (NYSE:CODI) on behalf of Compass stockholders. Our investigation concerns whether Compass has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. The investigation focuses on whether the Company issued false and/or mi ...

Compass, Inc. (COMP) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.67%. A quarter ago, it was expected that this company would post a loss of $0.09 per share when it actually produced a loss of $0.08, delivering a surprise of 11.11%.Over the last four quarters, the company has surpassed ...

LOS ANGELES, May 8, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Compass Diversified ("Compass" or "the Company") (NYSE: CODI) for violations of the securities laws.INVESTIGATION DETAILS: According to the Company, its investigation "has preliminarily identified irregularities in Lugano's non-CODI financing, accounting, and inventory practices," adding that, "Effective May 7, 2025, Lugano's founder and CEO, Moti Ferder, resigned from all of his po ...

Revenue in Q1 Grew 28.7% YoY and Organic Revenue Grew 14.6% YoY Quarterly Market Share Grew 125bps YoY to a Record 6.0%; Organic Share Was Up 82bpsOperating Cash Flow Grew 169% YoY to a Record $23.1 Million in Q1NEW YORK, May 8, 2025 /PRNewswire/ -- Compass, Inc. (NYSE: COMP) ("Compass" or "the Company"), a leading tech-enabled real estate services company that includes the largest residential real estate brokerage in the United States by sales volume1, announced its financial results for the first quarter ...

Momentum investors typically don't time the market or "buy low and sell high." In other words, they avoid betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time.Everyone likes betting on fast-moving trending stocks, but it isn't easy to determine the right entry point. These stocks often lose momentum when their future growth potential fails to justify their swelled-up valuation. In that phase ...

The market expects Compass, Inc. (COMP) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 8, 2025, might help the stock move higher if these key numbers are be ...

NEW YORK, April 30, 2025 /PRNewswire/ -- Compass, Inc. (NYSE: COMP) ("Compass"), a leading tech-enabled real estate services company that includes the largest residential real estate brokerage in the United States by sales volume1 announces the participation of CEO & Founder Robert Reffkin and CFO Kalani Reelitz at the 53rd Annual J.P. Morgan TMC Conference. The event will take place on May 14, 2025 at the Westin Seaport District Hotel in Boston.Reffkin will be participating in a fireside chat at 3:00 p.m. ...

BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical- stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced its poster presentation entitled "Enhanced Efficacy of CTX-471, A CD137 Agonist Antibody, In Models of Immune Checkpoint Failure Via Simultaneous Blockade of Neo-Angiogenesis" at the American Association for Cancer Research (AACR) Annual Meeting, from April 25–30, 2025, at the McCormick Place Co ...

Core Insights - The field of psychedelic medicine is emerging, attracting investor interest due to its potential for growth and innovation [1] - Compass Pathways experienced a 13% increase in share price following the announcement of a completed step in its clinical trial [1] Company Developments - Compass Pathways has completed dosing in a late-stage clinical trial for its psilocybin treatment, COMP005 [2] - The phase 3 trial involves 258 patients with moderate to severe depression who have not responded to at least two prior treatments, with dosing conducted at 32 sites in the U.S. [3][4] - The company is expected to publish six-week primary endpoint results by the end of June [3] Industry Context - The CEO of Compass Pathways emphasized the milestone as critical in addressing the unmet need in treatment-resistant depression, highlighting the legitimacy of psychedelics as potential therapies for serious psychological disorders [5]

Group 1 - Compass, Inc. is the largest residential real estate brokerage in the United States by sales volume, as ranked by Real Trends for the fourth consecutive year in April 2025 [1][3] - The company will release its first quarter 2025 financial results after market close on May 8, 2025, followed by a conference call and webcast at 5:00 p.m. ET [1] - Compass provides a tech-enabled platform that supports residential real estate agents with cloud-based software for various functions, enhancing efficiency and service delivery [1] Group 2 - The Compass network includes Christie's International Real Estate, which has over 100 independently owned brokerage affiliates in 50 countries and territories [1] - Investors are encouraged to monitor Compass' Investor Relations website for important disclosures and updates [2] - An audio recording of the upcoming conference call will be available for replay for 90 days after the event [3]